SCHEMBL3351538

SCHEMBL3351538

O=C(O)NCCC(O)NCc1cccc(OC(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.53
CNR1 P21554 2/20 0.47
ROCK2 O75116 1/20 0.47
ROCK1 Q13464 1/20 0.47
SCN9A Q15858 2/20 0.47
KDM5A P29375 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
KDM5B Q9UGL1 1/20 0.47
VNN1 O95497 1/20 0.46
CETP P11597 2/20 0.44
PPARG P37231 1/20 0.44
PPARD Q03181 1/20 0.44
PPARA Q07869 1/20 0.44
GLS O94925 2/20 0.43
CARM1 Q86X55 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
ABCB1 P08183 1/20 0.42
KCNB1 Q14721 1/20 0.42
MMP13 P45452 1/20 0.42
AKR1C3 P42330 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3350274 0.85 EPHX2 (0.46) SCN9AVNN1PPARGPPARDPPARA
SCHEMBL3348575 0.84 ALDH1A1 (0.55) MMP13
SCHEMBL3355242 0.82 BCHE (0.49) MAPK14
SCHEMBL5384715 0.81 MAPK14 (0.49) MAPK14ROCK2ROCK1SCN9AKDM5A
SCHEMBL3356519 0.76 PPARG (0.46) SCN9AVNN1PPARG
SCHEMBL14966126 0.76 CETP (0.52) MAPK14ROCK2ROCK1KDM5AKDM4C
SCHEMBL23195276 0.75 MAPK14 (0.65) MAPK14CNR1ROCK2ROCK1SCN9A
SCHEMBL30152446 0.75 MAPK14 (0.65) MAPK14CNR1ROCK2ROCK1SCN9A
SCHEMBL3351114 0.74 KCNH2 (0.45) MAPK14CNR1PPARGPPARDPPARA
SCHEMBL2245674 0.74 MAPK14 (0.49) MAPK14ROCK2ROCK1SCN9AKDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP MAPK14 4454/4885CNR1 605/4885ROCK2 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.